Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous platelet-rich plasma eye drops (BioTears)
- Development stage
- Phase 1
- Lead developer
- BioTears
- Administration
- Ophthalmic
01
Overview
BioTears is a personalized ophthalmic treatment consisting of autologous platelet-rich plasma (PRP) eye drops. These drops are prepared by drawing a patient's own blood, centrifuging it to concentrate the platelets, and then formulating the resulting plasma into a topical solution. PRP contains a high concentration of endogenous growth factors (such as TGF-β, PDGF, and EGF) and cytokines that promote corneal epithelial healing, reduce inflammation, and improve the ocular surface microenvironment. It is primarily used for the treatment of severe dry eye disease, persistent epithelial defects, and other ocular surface disorders where conventional artificial tears are insufficient. As an autologous product, it minimizes the risk of immunological reactions or transmission of infectious diseases.
- Brand names
- BioTears
- Other names
- PRP Eye DropsPlatelet-Rich Plasma Eye DropsAutologous Platelet-Rich Plasma Eye Drops
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)FGFR3 (Fibroblast growth factor receptor 3)IGF-1R (Insulin-like growth factor 1 receptor)PDGFRA (Platelet-derived growth factor receptor alpha)TGFBR (TGF-beta receptor)FGFR (FGFR family)VEGFR (VEGFR family)
Beyond the preview
Go deeper on autologous platelet-rich plasma eye drops (BioTears).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous platelet-rich plasma eye drops (BioTears).